Status:

COMPLETED

Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder

Lead Sponsor:

Samsung Medical Center

Conditions:

Panic Disorder

Eligibility:

All Genders

20-60 years

Phase:

PHASE4

Brief Summary

Panic disorder is one of the most prevalent and disabling psychiatric disorders. Brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal...

Eligibility Criteria

Inclusion

  • panic disorder 20-60 years

Exclusion

  • history of major psychosis (schizophrenia or bipolar disorder), social phobia, obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic stress disorder, alcohol abuse and dependence, current regular use of benzodiazepines
  • less than 17 on the HAM-D

Key Trial Info

Start Date :

January 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

37 Patients enrolled

Trial Details

Trial ID

NCT00767754

Start Date

January 1 2007

End Date

December 1 2008

Last Update

July 25 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Samsung Medical Center

Seoul, South Korea, 135-710